Cargando…
Outcomes in Pregnant Persons Immunized with a Cell-Based Quadrivalent Inactivated Influenza Vaccine: A Prospective Observational Cohort Study
Objective: To evaluate pregnancy and infant outcomes among persons immunized with a cell-based quadrivalent inactivated influenza vaccine (IIV4c) during routine pregnancy care. Design: Prospective observational cohort. Setting: US-based obstetrics/gynecology clinics. Population: Pregnant persons. Th...
Autores principales: | Robinson, Christopher, Van Boxmeer, Josephine, Tilson, Hugh, Scialli, Anthony, Vanchiere, John A., Ides, Ellis, Sawlwin, Daphne, Molrine, Deborah, Hohenboken, Matthew, Edelman, Jonathan, Albano, Jessica D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612226/ https://www.ncbi.nlm.nih.gov/pubmed/36298465 http://dx.doi.org/10.3390/vaccines10101600 |
Ejemplares similares
-
A Prospective Cohort Study on Pregnancy Outcomes of Persons Immunized with a Seasonal Quadrivalent Inactivated Influenza Vaccine during Pregnancy
por: Robinson, Christopher, et al.
Publicado: (2022) -
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023) -
Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults
por: Versage, Eve, et al.
Publicado: (2021) -
Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2022) -
Cell-Based Quadrivalent Inactivated Influenza
Virus Vaccine (Flucelvax(®) Tetra/Flucelvax
Quadrivalent(®)): A Review in the Prevention of
Influenza
por: Lamb, Yvette N.
Publicado: (2019)